

CURRICULUM VITAE

Prof. dr. TENG Y. K. Onno, MD PhD
Nephrologist
Department Medicine - Nephrology
Leiden University Medical Center (LUMC)

May 1, 2025



PERSONAL INFORMATION

Titles	Professor, MD, PhD
First names	Yoe Kie Onno
Surname	Teng
Birth date	January 28, 1981
Nationality	Dutch
Professional address	Leiden University Medical Center Department of Nephrology (C7-Q) Albinusdreef 2 2333 ZA Leiden The Netherlands T: 00 31 71 5263314 / 001234 56789 

Professional web profiles

Publons Account	https://publons.com/researcher/1534334/yoe-kie-onno-teng/
Orcid ID	https://orcid.org/0000-0001-9920-2195
LinkedIn	linkedin.com/in/y-k-onno-teng-6382155

Narrative summary

*** Clinical activities:** I am a full professor in Nephrology at the department of Internal Medicine of the Leiden University Medical Center (LUMC). I am the head of the national and European recognized center of expertise for Lupus, Vasculitis and Complement-mediated Systemic diseases (LuVaCs). I coordinate a clinical, multidisciplinary in-hospital team providing expert care for patients with (severe) systemic autoimmune diseases involving collaborations with the departments of Rheumatology, Vascular medicine, Obstetrics & Gynaecology, Hematology, Ear-Nose-Throat (ENT), Pulmonology and Immunology. A large focus is on patients with systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS, ANCA-associated vasculitis (AAV) and complement-mediated diseases which can present as renal autoimmune disease (also referred to as immune-mediated kidney diseases - IMKDs).

*** Scientific activities:** Since the beginning from my academic career, I have organized a clinical research program for the development of novel treatment strategies in patients with a renal autoimmune diseases including lupus nephritis, ANCA associated vasculitis and complement-mediated kidney diseases. Simultaneously, I conduct a translational research program focused on neutrophil extracellular traps, B-cell & plasma cell and complement immunology which enables us to perform innovative immunomonitoring in patients with LuVaCs managed with novel treatment strategies.

*** Teaching activities:** I am actively involved as clinical teacher for Nephrology, Immunology and Basic Physiology & Anatomy in the curriculum of Medicine at the Leiden University. I teach and supervise medical students for their scientific internships as well as clinical internships as part of the Medicine curriculum. Clinical bedside teaching of the LUMC Internal Medicine residents. I have supervised multiple MD-PhD students to date.

EXECUTIVE SUMMARY OF CV

Academic Appointments

March 2023- present	Professor in Nephrology focused at Renal Autoimmune diseases
Jan 2021 - present	Member of the Research Management Team (RMT), department of Internal Medicine
May 2019 - present	Head of Center of Expertise for Lupus- Vasculitis- and Complement-mediated Systemic diseases (LuVaCs)
2021	LuVaCs CoE: National recognition by National Federation of University Medical Centers (NFU)
2022	LuVaCs CoE: International recognition by European Reference Networks ERK-NET and RITA
May 2014 – May 2022	Chief Outpatient Clinic Nephrology
Jan 2014 – present	Nephrologist

Current clinical and research responsibilities

2022 – present	<p>President for the AutoImmune Research & Collaboration Hub (ARCH) Foundation</p> <p><i>National foundation aimed at improving the national care system for patients with rare systemic autoimmune diseases funded by Dutch Arthritis Foundation, supported by the Dutch Society for Rheumatology and the Dutch Society for Nephrology</i></p>
2018 - 2022	<p>Regional and National Lead on several ARCH-projects to improve the national care system for patients with rare systemic autoimmune diseases funded by Dutch Arthritis Foundation:</p> <ul style="list-style-type: none">- on ANCA-associated vasculitis (AAV):<ul style="list-style-type: none">* National consensus on the diagnosis and treatment of AAV in NL* Conducting a national audit on clinical practice variation in AAV care- on regional networks of expertise:<ul style="list-style-type: none">* organizing, structuring, coordinating and collaborating 6 regional networks throughout the Netherlands- on ARCH digital portal for regional, multidisciplinary meetings for patients with rare systemic autoimmune diseases:<ul style="list-style-type: none">* co-creating a digital application for standardised medical data sharing between professionals and hospitals
2014 – present	<p>National and international Principal Investigator for several phase 3, randomized studies on novel treatment strategies for patients with</p> <ul style="list-style-type: none">- Lupus Nephritis:<ul style="list-style-type: none">* Synbiose 1 (rituximab + belimumab), LUMC* Synbiose 2 (belimumab + rituximab), LUMC & Netherlands* BLISS-LN (belimumab), global RCT* BLISS-BELIEVE (belimumab + rituximab), global RCT* AURORA-1 (voclosporin), global RCT* AURORA-2 (voclosporin extended use), global RCT* SIRIUS-LN (ianalumab), global RCT- ANCA-associated vasculitis:<ul style="list-style-type: none">* MoRiA (rituximab), LUMC* ENDURANCE (rituximab + cyclophosphamide), LUMC & Netherlands

- * ADVOCATE (avacopan), global RCT
- * AVAC-EUR (avacopan), European multicentre retrospective study
- * Clear-study (avacopan), global RCT
- * LNP023 (iptacopan), global RCT
- Complement-mediated diseases:
 - * APPEAR-C3G (iptacopan), global RCT
 - * Comp cure, observational European study on C3G
- Other:
 - * Good-Ides2 (imfilidase), European RCT
 - * VOCOVID (voclosporin), LUMC

2014 - present Direct supervisor and co-promotor of 13 MD-PhD students (3 completed)

2014 - present Expert Consultant to European Commission, ZorgInstituut Nederland (ZiN – Ministry of Health), Alexion Pharmaceuticals, Aurinia Pharmaceuticals, GlaxoSmithKline, KezarBio, Novartis, Otsuka Pharmaceuticals, Vifor Pharma

List of publications

Please click on link for a continuous updated list of publications in Web of Science:

Publons Account <https://publons.com/researcher/1534334/yoe-kie-onno-teng/>

Orcid ID <https://orcid.org/0000-0001-9920-2195>

Citation report Web of Science

<i>Date: 23 February 2024</i>	
Publications	132
Citing Articles	2824 (total)
	2770 (without self-citations)
Times Cited	3834 (total)
	3723 (without self-citations)
Average Citations per Item	29.05
H-index	30

Top-5 Influential publications, including number of citations

<i>Date: January 2025</i>		
No.	Authors, Title, Journal	Citations
1	<p>2019 Update of the Joint European League Against Rheumatism and European Renal Association– European Dialysis and Transplant Association (EULAR/ERA–EDTA) recommendations for the management of lupus nephritis. <u>Ann Rheum Dis 2020</u>; 79: 713–723. doi:10.1136/annrheumdis-2020-216924</p> <p>Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, Boletis J, Frangou E, Houssiau FA, Hollis J, Karras A, Marchiori F, Marks SD, Moroni G, Mosca M, Parodis I, Praga M, Schneider M, Smolen JS, Tesar V, Trachana M, van Vollenhoven RF, Voskuyl AE, Teng YKO, van Leeuw B, Bertsias G, Jayne D, Boumpas DT.</p>	413
2	<p><i>Treatment of Lupus Nephritis with Belimumab: A 2-year randomized controlled trial.</i> <u>New Engl J Med 2020</u> sept 17; 383 (12): 1117-1128</p>	400

	Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO , Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth D.	
3	<i>Voclosporin efficacy and safety in lupus nephritis (AURORA 1): A phase 3 double-blind, randomised, multi-centre, placebo-controlled trial.</i> <u>Lancet 2021</u> , 397 (10289), pp.2070-2080 Rovin BH, Teng YKO , Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Haplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB.	199
4	<i>The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.</i> <u>J Autoimmun 2018</u> ; 91: 45-54 Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO .	94
5	<i>EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update.</i> <u>Ann Rheum Dis 2023</u> ; DOI 10.1136/ard-2022-223764 Hellmich, B; Sanchez-Alamo, B; Schirmer, JH; Berti, A; Blockmans, D; Cid, MC; Holle, JU; Hollinger, N; Karadag, O; Kronbichler, A; Little, MA; Luqmani, RA; Mahr, A; Merkel, PA; Mohammad, AJ; Monti, S; Mukhtyar, CB; Musial, J; Price-Kuehne, F; Segelmark, M; Teng, YKO ; Terrier, B; Tomasson, G; Vaglio, A; Vassilopoulos, D; Verhoeven, P; Jayne, D	76

Top-5 First/Last author Influential publications, including number of citations

Date: January 2025

No.	Authors, Title, Journal	Citations
1	<i>Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.</i> <u>Arthritis Rheumatol 2007</u> ; 12: 3909-3918 Teng YK , Levarht EWN; Hashemi M, Bajema IM, Toes REM, Huizinga TWJ, van Laar JM.	139
2	<i>The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.</i> <u>J Autoimmun 2018</u> ; 91: 45-54 Kraaij T, Kamerling SWA, de Rooij ENM, van Daele PLA, Bredewold OW, Bakker JA, Bajema IM, Scherer HU, Toes REM, Huizinga TJW, Rabelink TJ, van Kooten C, Teng YKO .	101
3	<i>Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.</i> <u>BMJ Open 2019</u> Mar 20; 9 (3): e025687 Teng YKO , Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.	83
4	<i>A novel method for high-throughput detection and quantification of neutrophil extracellular traps reveals ROS-independent NET release with immune complexes.</i> <u>Autoimmunity reviews 2016</u> ; 15(6): 577-584. Kraaij T, Tengström FC, Kamerling SWA, Pusey CD, Scherer HU, Toes REM, Rabelink TJ, van Kooten C, Teng YKO	68
5	<i>Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA.</i> <u>Kidney Int 2018</u> ; 94(1): 139-149 Kraaij T, Kamerling SWA, van Dam LS, Bakker JA, Bajema IM, Page T, Brunini F, Pusey CD, Toes REM, Scherer HU, Rabelink TJ, van Kooten C, Teng YKO .	66

department Nierziekten
postal zone C7-Q
sender prof.dr. Y.K.O. Teng

to SLEuro Executive Committee

our reference

your reference

datum January 17, 2026
subject Application for 2nd term in Executive
Committee
pages 1

Dear colleagues,

With this letter, I would like to apply for the executive committee of SLEuro upon proposal of Professor L. Ines.

European collaboration is self-evident to foster the community of clinicians, researchers and educators to improve the awareness, care and outcome for lupus patients. It would be an honor to contribute to this endeavour from SLEuro. I hope that my contribution can impact *multidisciplinary* collaborations at an international level in the field of SLE and thereby promote, improve and sustain a broad community of colleagues committed to the mission of SLEuro.

In all modesty, I hope you will accept my application and accompanying CV as witness of my dedication to continuously encourage research and improvement of care for SLE patients.

Yours sincerely,



prof.dr. Y.K.O. Teng